KONICA MINOLTA 3rd Quarter/FY2019 ending in March 2020 Consolidated Financial Results  


New Business

Prev. Page Next Page Download the PDF
In Bio-healthcare, the number of RNA testing that have been differentiated by Ambry's advanced technologies has seen a greater-than-anticipated increase . In the first half, we limited the medical institutions we provided, but since Sep., when we obtained the CPT codes required for insurance claims in the United States, we have removed the restrictions and made a full launch. We succeeded in expanding the number of medical institutions we provide.
CARE program, which aims to expand the target market for genetic diagnostics to healthy people, has taken time and is not yet reached the plan, as it takes time to develop the infrastructure to scale up testing for checkup market, but is increasing.
Pharmaceutical development support developed by Invicro is as explained earlier.
In Workplace Hub, the number of customers has increased, driven by Europe, while the results has remained far below the target. In the United States, which had been lagging behind, the number of pipeline customers has begun to increase in 3Q. We will continue to increase the number of customers by offering starter packages and industry-specific solutions in each country.